BioInvent has carried out a directed issue

BioInvent has carried out a directed placement of new shares of approximately MSEK 300 to international and Swedish institutional investors.

BioInvent is a clinical stage company focused on the development of novel, first-in-class immuno-modulatory antibodies for the treatment of cancer. BioInvent’s shares are listed on Nasdaq Stockholm (BINV).

BioInvent was represented by Mannheimer Swartling.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.